Repaglinide Tablet
Product Images NDC 71335-2554

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Repaglinide (NDC 71335-2554). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713352554)

Repaglinide Tablets USP 0.5 mg oral tablets label showing NDC 71335-2554-1. The label indicates 30 tablets per container, repackaged by Bryant Ranch Prepack, Inc. and manufactured by Macleods Pharmaceuticals Ltd. Warnings include storage from 20° to 25°C and keeping containers tightly closed and out of reach of children. The label includes QR codes and barcodes.*

FDA Label Image

505 (Repaglinide Figure 1)

A line graph showing the change in HbA1c percentage over a 24-week treatment period. The graph compares three groups: Repaglinide plus Pioglitazone, Repaglinide alone, and Pioglitazone alone. The x-axis represents treatment weeks from 0 to 24, and the y-axis shows the percentage change in HbA1c from 0 to -2.*

FDA Label Image

Str (Repaglinide Str)

Chemical structure of repaglinide, showing its molecular composition with labeled atoms and bonds depicting the arrangement of functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.